Total raised
—
Stage
Pre-Funding
Founded
2011
Headcount
6
HQ
Kfar Truman
Sector
Health Tech & Life Sciences
About
EasyNOTES Medical is engaged in the development, manufacture, and marketing of medical devices for the endoscopic treatment of Type 2 diabetes. The companys EasyByPass is a simple, nonsurgical, endoscopic procedure for treating Type 2 diabetes. The procedure is designed to have a low risk of complications, minimize inconvenience to the patient, eliminate the need for hospitalization, and utilize low-cost resources.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is easyNOTES Medical's primary focus?
- easyNOTES Medical is engaged in the development, manufacture, and marketing of medical devices for the endoscopic treatment of Type 2 diabetes.
- What is the status of easyNOTES Medical?
- easyNOTES Medical is currently inactive, having ceased operations in October 2022.
- When was easyNOTES Medical founded?
- easyNOTES Medical was founded in January 2011.
- Where is easyNOTES Medical headquartered?
- easyNOTES Medical is headquartered in Kfar Truman, Israel, at HaEla Street 30.
- What is the name of easyNOTES Medical's main product?
- easyNOTES Medical's main product is EasyByPass, an endoscopic procedure for treating Type 2 diabetes.
- What stage is easyNOTES Medical's product in?
- The EasyByPass product is in the clinical trial stage.
- How many employees did easyNOTES Medical have?
- easyNOTES Medical had 6 employees.
- Who is a founder of easyNOTES Medical?
- Moshe Mizrahi is a founder of easyNOTES Medical.
- What is easyNOTES Medical's current funding stage?
- easyNOTES Medical is in the Pre-Funding stage.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Tags
medical-deviceshospitalsendoscopypreventiongastroenterologydiabetesnon-surgicalclinicspatientsminimally-invasivehealthcare-providerstreatmentsmedical-technologiestype-2-diabetes